{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:38:59Z","timestamp":1793392739835,"version":"4.5.0"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T00:00:00Z","timestamp":1713484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>The Spasticity-Plus Syndrome (SPS) in multiple sclerosis (MS) refers to a combination of spasticity and other signs\/symptoms such as spasms, cramps, bladder dysfunction, tremor, sleep disorder, pain, and fatigue. The main purpose is to develop a user-friendly tool that could help neurologists to detect SPS in MS patients as soon as possible.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A survey research based on a conjoint analysis approach was used. An orthogonal factorial design was employed to form 12 patient profiles combining, at random, the eight principal SPS signs\/symptoms. Expert neurologists evaluated in a survey and a logistic regression model determined the weight of each SPS sign\/symptom, classifying profiles as SPS or not.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>72 neurologists participated in the survey answering the conjoint exercise. Logistic regression results of the survey showed the relative contribution of each sign\/symptom to the classification as SPS. Spasticity was the most influential sign, followed by spasms, tremor, cramps, and bladder dysfunction. The goodness of fit of the model was appropriate (AUC\u2009=\u20090.816). Concordance between the experts\u2019 evaluation vs. model estimation showed strong Pearson\u2019s (<jats:italic>r<\/jats:italic>\u2009=\u20090.936) and Spearman\u2019s (<jats:italic>r<\/jats:italic>\u2009=\u20090.893) correlation coefficients. The application of the algorithm provides with a probability of showing SPS and the following ranges are proposed to interpret the results: high (&amp;gt; 60%), moderate (30\u201360%), or low (&amp;lt; 30%) probability of SPS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>This study offers an algorithmic tool to help healthcare professionals to identify SPS in MS patients. The use of this tool could simplify the management of SPS, reducing side effects related with polypharmacotherapy.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2024.1371644","type":"journal-article","created":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T05:09:05Z","timestamp":1713503345000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Practical tool to identify Spasticity-Plus Syndrome amongst patients with multiple sclerosis. Algorithm development based on a conjoint analysis"],"prefix":"10.3389","volume":"15","author":[{"given":"\u00d3scar","family":"Fern\u00e1ndez Fern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucienne","family":"Costa-Frossard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"Mart\u00ednez Gin\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paloma","family":"Montero Escribano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Prieto Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Llu\u00eds","family":"Rami\u00f3-Torrent\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda","family":"Aladro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Alonso Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"\u00c1lvarez Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Labiano-Fontcuberta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lamberto","family":"Landete Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambrosio","family":"Miralles Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Moral Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Oliva-Nacarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,19]]},"reference":[{"key":"ref1","first-page":"177","volume-title":"Illustrated Medical Dictionary","year":"2002"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3389\/fneur.2020.00152","article-title":"The broad concept of \u201cspasticity-plus syndrome\u201d in multiple sclerosis: a possible new concept in the Management of Multiple Sclerosis Symptoms","volume":"11","author":"Fern\u00e1ndez","year":"2020","journal-title":"Front Neurol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"722801","DOI":"10.3389\/fneur.2021.722801","article-title":"Integrated Management of Multiple Sclerosis Spasticity and Associated Symptoms Using the spasticity-plus syndrome concept: results of a structured specialists\u2019 discussion using the Workmat\u00ae methodology","volume":"12","author":"Fernandez","year":"2021","journal-title":"Front Neurol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ene.13819","article-title":"Multiple sclerosis\u2014a review","volume":"26","author":"Dobson","year":"2019","journal-title":"Eur J Neurol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1080\/00207454.2018.1481066","article-title":"Sativex\u00ae as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial","volume":"129","author":"Markov\u00e0","year":"2019","journal-title":"Int J Neurosci"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1111\/j.1468-1331.2010.03328.x","article-title":"A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(\u00ae)), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis","volume":"18","author":"Novotna","year":"2011","journal-title":"Eur J Neurol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/j.1468-1331.2006.01639.x","article-title":"Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis","volume":"14","author":"Collin","year":"2007","journal-title":"Eur J Neurol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1179\/016164109X12590518685660","article-title":"A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis","volume":"32","author":"Collin","year":"2010","journal-title":"Neurol Res"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1191\/1352458504ms1082oa","article-title":"Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients","volume":"10","author":"Wade","year":"2004","journal-title":"Mult Scler"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1111\/ene.15412","article-title":"A real-world evidence study of nabiximols in multiple sclerosis patients with resistant spasticity: analysis in relation to the newly described 'spasticity-plus syndrome'","volume":"29","author":"Patti","year":"2022","journal-title":"Eur J Neurol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2217\/nmt-2023-0040","article-title":"Patient-reported benefits from nabiximols treatment in multiple sclerosis-related spasticity exceed conventional measures","volume":"14","author":"Haupts","year":"2024","journal-title":"Neurodegener Dis Manag"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e2947","DOI":"10.1002\/brb3.2947","article-title":"Non-interventional, prospective, observational study on spasticity-associated symptom control with nabiximols as add-on therapy in patients with multiple sclerosis spasticity in Austria","volume":"13","author":"Guger","year":"2023","journal-title":"Brain Behav"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1159\/000367618","article-title":"Advances in the management of MS spasticity: recent observational studies","volume":"72","author":"Fern\u00e1ndez","year":"2014","journal-title":"Eur Neurol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1136\/bmj.320.7248.1530","article-title":"Using conjoint analysis to elicit preferences for health care","volume":"320","author":"Ryan","year":"2000","journal-title":"BMJ"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"802918","DOI":"10.3389\/fneur.2021.802918","article-title":"Theoretical and therapeutic implications of the spasticity-plus syndrome model in multiple sclerosis","volume":"12","author":"Bruno","year":"2021","journal-title":"Front Neurol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.sedene.2023.03.002","article-title":"Estudio retrospectivo sobre la presencia del s\u00edndrome de spasticity-plus en la consulta de la enfermera de pr\u00e1ctica avanzada en esclerosis m\u00faltiple","author":"Goicochea Brice\u00f1o","year":"2023","journal-title":"Rev Cient Soc Esp Enferm Neurol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"958665","DOI":"10.3389\/fneur.2022.958665","article-title":"Clinical insights on the spasticity-plus syndrome in multiple sclerosis","volume":"13","author":"Alami Marrouni","year":"2022","journal-title":"Front Neurol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2217\/nmt-2022-0002","article-title":"Evidence-based management of multiple sclerosis spasticity with nabiximols oromucosal spray in clinical practice: a 10-year recap","volume":"12","author":"Chan","year":"2022","journal-title":"Neurodegen Dis Manag"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1007\/s10072-020-04413-6","article-title":"Effects of THC\/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: results from a retrospective multicenter study","volume":"41","author":"Patti","year":"2020","journal-title":"Neurol Sci"},{"key":"ref20","first-page":"239","article-title":"Polypharmacy in multiple sclerosis: current knowledge and future directions","volume":"118","author":"Thelen","year":"2021","journal-title":"Mo Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1080\/14740338.2020.1720646","article-title":"Polypharmacy among patients with multiple sclerosis: a qualitative systematic review","volume":"19","author":"Frahm","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1179\/1743132815Y.0000000036","article-title":"Medication use in a large international sample of people with multiple sclerosis: associations with quality of life, relapse rate and disability","volume":"37","author":"Jelinek","year":"2015","journal-title":"Neurol Res"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1371644\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T05:09:08Z","timestamp":1713503348000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1371644\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,19]]},"references-count":22,"alternative-id":["10.3389\/fneur.2024.1371644"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2024.1371644","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,19]]},"article-number":"1371644"}}